- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02490813
Pilot Study on Traditional Chinese Medicine and Food Allergy (TCMFA)
Recently, there has been an increasing interest in using traditional Chinese medicine for food allergy. The Harvard group has successfully demonstrated the Food Allergy Herbal Formula - FAHF2 completely blocked peanut-induced anaphylaxis in a murine model, and currently being studied in human. Therefore, in collaboration with the Institute of Chinese Medicine, CUHK, the investigators have developed a more simplified Chinese herbal formula - X (CHFX), containing four food-grade Chinese herbs, Wu-mei (Fructus Pruni Mume); Ling-zhi (Gonoderma); Huang-bai (Cortex Phellodendron) and Zhi-su (Perilla frutescens).
In the present study, the investigators would like to examine whether there is reduction in allergic symptoms in food challenge after administering the CHFX for 8 weeks. There will be pre- and post- CHFX food challenges and other related tests.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The investigators aim to recruit 24 subjects for the present study. Subjects will be randomized into two groups, control group (n=12) and treatment group (n=12). At recruitment all subjects will be required to stop anti-allergic medicines and Chinese medicines as a wash out period for two weeks (week 1 and week 2). They will be required to keep a record of their symptoms and peak flow rates twice daily throughout the entire study. Skin prick test will be performed with a panel of commercially available skin test solutions for cod, shrimp and crab (ALK). Total and specific IgE as well as total and specific IgG4 for fish and shellfish will be measured (by the HKSH laboratory or CUHK laboratory). Graded open cod, shrimp or crab challenge will be performed as described later at HKSH in each patient to determine the baseline tolerance level to fish or shellfish, using freeze-dried cod, shrimp or crab as appropriate.
After determining the baseline tolerance level, subjects in the treatment group will take 2 grams of the CHFX or placebo daily for 8 weeks (week 4 to week 11). The placebo powder consists of food grade medicinal starch blended with coloring agent. After the 8 weeks of treatment, skin prick tests, blood tests as at baseline and oral challenges will be repeated (week 12). During the study subjects will be requested to consume their normal diet but avoiding fish and shellfish, with no consumption of any other Chinese herbal medication. They can take anti-allergic medicines as necessary but will note when medicines are taken in their symptom and peak flow diary.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: June Chan, Master
- Phone Number: 2835-8430
- Email: junechan@hksh.com
Study Contact Backup
- Name: Tak Hong Lee, Doctor
- Phone Number: 2835-8430
- Email: thlee@hksh.com
Study Locations
-
-
-
Happy Valley, Hong Kong
- Hong Kong Sanatorium & Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Age 8 years or older with a history of allergic reaction to cod, shrimp or crab, manifested by any of the following: urticaria, angioedema, asthma or anaphylaxis, within 60 mins of ingestion.
- Having a positive skin prick test to the cod, shrimp or crab as defined by a weal diameter 3 mm greater than the diluent control.
- Having a positive oral challenge with freeze-dried cod, shrimp or crab.
- Asthma must be under control with a FEV1 of at least 80% predicted value.
- Aspirin, anti-histamines/anti-allergic medicines and antidepressants are not permitted for 3 days, one week and two weeks, respectively, before skin testing or oral food challenge.
Exclusion Criteria:
- Pregnancy.
- Requiring systemic glucocorticoids, beta-blockers and ACE inhibitors.
- Having poorly controlled asthma, poorly controlled atopic dermatitis prior to study.
- Inability to discontinue antihistamines or other medication for skin testing and oral challenges.
- Unable to comply with the study protocol for any reason.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Placebo Comparator: Control
This arm will receive the placebo.
|
Placebo will be starch with colorings
|
Experimental: Treatment - Chinese Herbal Formula - X
This arm will receive the Chinese Herbal Formula - CHFX as treatment to their existing fish, shrimp or crab allergy.
|
Wu Mei (Fructus Pruni Mume), Ling Zhi (Gonoderma), Huang Bai (Cortex Phellodendron), and Zhi Su (Perilla frutescens).
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Tolerance to existing allergen
Time Frame: 8 weeks
|
subjects will be accessed on tolerance to existing allergen via opened oral food challenge
|
8 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Skin prick test result
Time Frame: 8 weeks
|
Skin prick test result to existing allergen
|
8 weeks
|
Blood test - IgE result
Time Frame: 8 weeks
|
Specific IgE test result to existing allergen
|
8 weeks
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: June Chan, Master, Hong Kong Sanatorium & Hospital
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- ALC-002
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Allergy to Fish
-
George StavroulakisOdense University Hospital; Medical University of Lodz; National and Kapodistrian... and other collaboratorsCompletedFood Allergy to FishDenmark, Greece, Iceland, Netherlands, Poland, Spain
-
University Hospital of North NorwayUniversity of Tromso; University of Manchester; Helse NordCompleted
-
Chinese University of Hong KongRecruiting
-
Rigshospitalet, DenmarkOdense University Hospital; University Hospital, Gentofte, CopenhagenCompleted
-
University Hospital, LilleHôpital Cochin; Institut Pasteur de Lille; Région Nord-Pas de Calais, France; A...CompletedAllergy | Allergy to Fish | AnisakisFrance
-
Abionic SAJohns Hopkins University; NAMSAWithdrawnAllergy | Allergic Asthma | Allergy to Cats | Allergy to House Dust | Allergy Cockroach | Allergy to Dog Dander (Finding) | Allergy MoldUnited States
-
Abionic SAJohns Hopkins University; NAMSAWithdrawnAllergy | Allergic Asthma | Allergy to Cats | Allergy to House Dust | Allergy to Dog Dander | Allergy CockroachUnited States
-
Sayantani B. SindherNational Institute of Allergy and Infectious Diseases (NIAID)TerminatedAllergy;Food | Allergy to Shrimp | Allergy to Cashew Nut (Disorder)United States
-
University Hospital, RouenCompletedAllergy to Egg | Allergy to PeanutFrance
-
University of ZurichImVision AGCompletedAllergy to CatsSwitzerland
Clinical Trials on Placebo
-
SamA Pharmaceutical Co., LtdUnknownAcute Bronchitis | Acute Upper Respiratory Tract InfectionKorea, Republic of
-
National Institute on Drug Abuse (NIDA)CompletedCannabis UseUnited States
-
AstraZenecaParexel; Spandauer Damm 130; 14050; Berlin, GermanyCompletedMale Subjects With Type II Diabetes (T2DM)Germany
-
Heptares Therapeutics LimitedCompletedPharmacokinetics | Safety IssuesUnited Kingdom
-
GlaxoSmithKlineCompletedPulmonary Disease, Chronic ObstructiveUnited Kingdom, Netherlands
-
ItalfarmacoCompletedBecker Muscular DystrophyNetherlands, Italy
-
Shijiazhuang Yiling Pharmaceutical Co. LtdXuanwu Hospital, BeijingCompleted
-
GlaxoSmithKlineCompletedInfections, BacterialUnited States
-
West Penn Allegheny Health SystemCompletedAsthma | Allergic RhinitisUnited States